Donna A Volpe

List of Publications by Year
in descending order

47 papers	2,201 citations	279798 23 h-index	265206 42 g-index
50 all docs	50 docs citations	50 times ranked	3109 citing authors

#	Article	IF	Citations
1	Characterization of a commercially available line of iPSC hepatocytes as models of hepatocyte function and toxicity for regulatory purposes. Journal of Pharmacological and Toxicological Methods, 2021, 110, 107083.	0.7	9
2	Advances in cell-based permeability assays to screen drugs for intestinal absorption. Expert Opinion on Drug Discovery, 2020, 15, 539-549.	5.0	33
3	Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients. JAMA - Journal of the American Medical Association, 2020, 323, 256.	7.4	151
4	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. PLoS ONE, 2020, 15, e0241362.	2.5	17
5	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
6	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
7	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
8	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
9	Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients. JAMA - Journal of the American Medical Association, 2019, 321, 2082.	7.4	207
10	The development of biological therapies for neurological diseases: moving on from previous failures. Expert Opinion on Drug Discovery, 2018, 13, 283-293.	5.0	10
11	Methadone Metabolism and Drug-Drug Interactions: InÂVitro and InÂVivo Literature Review. Journal of Pharmaceutical Sciences, 2018, 107, 2983-2991.	3.3	38
12	Application of in vitro CYP and transporter assays to predict clinical drugâ€“drug interactions. Bioanalysis, 2018, 10, 619-623.	1.5	8
13	Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 697-707.	5.0	3
14	In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemotherapy and Pharmacology, 2018, 82, 795-802.	2.3	33
15	Impact of the US FDA â€œBiopharmaceutics Classification Systemâ€•(BCS) Guidance on Global Drug Development. Molecular Pharmaceutics, 2017, 14, 4334-4338.	4.6	23
16	Evaluation of transporters in drug development: Current status and contemporary issues. Advanced Drug Delivery Reviews, 2017, 116, 100-118.	13.7	62
17	Transporter assays as useful in vitro tools in drug discovery and development. Expert Opinion on Drug Discovery, 2016, 11, 91-103.	5.0	29
18	Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination. AAPS Journal, 2014, 16, 172-180.	4.4	49

#	Article	IF	Citations
19	Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regulatory Toxicology and Pharmacology, 2014, 68, 297-303.	2.7	29
20	Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Medicinal Chemistry, 2011, 3, 2063-2077.	2.3	183
21	Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regulatory Toxicology and Pharmacology, 2011, 59, 385-390.	2.7	336
22	Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs. Drug Metabolism and Disposition, 2011, 39, 1196-1202.	3.3	91
23	Application of Method Suitability for Drug Permeability Classification. AAPS Journal, 2010, 12, 670-678.	4.4	92
24	Effect of altered temperature storage on thein vitrocellular uptake of liposome drug products. Journal of Liposome Research, 2010, 20, 178-182.	3.3	1
25	Variability in Caco-2 and MDCK Cell-Based Intestinal Permeability Assays. Journal of Pharmaceutical Sciences, 2008, 97, 712-725.	3.3	197
26	Comparison of the stability of split and intact gabapentin tablets. International Journal of Pharmaceutics, 2008, 350, 65-69.	5.2	19
27	Effect of Ethanol on Opioid Drug Permeability Through Caco-2 Cell Monolayers. AAPS Journal, 2008, 10, 360-362.	4.4	18
28	Drug Permeability Studies in Regulatory Biowaiver Applications. , 2008, , 665-680.		7
29	Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay. Clinical Research and Regulatory Affairs, 2007, 24, 39-47.	2.1	71
30	Biopharmaceutics Classification of Selected Î²-Blockers:â€‰ Solubility and Permeability Class Membership. Molecular Pharmaceutics, 2007, 4, 608-614.	4.6	83
31	Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1854-1859.	2.8	47
32	Permeability classification of representative fluoroquinolones by a cell culture method. AAPS PharmSci, 2004, 6, 1-6.	1.3	97
33	In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Cancer Chemotherapy and Pharmacology, 2004, 54, 89-94.	2.3	3
34	Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. Journal of Experimental Therapeutics and Oncology, 2003, 3, 169-184.	0.5	29
35	Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Annals of Oncology, 1998, 9, 357-364.	1.2	66
36	Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemotherapy and Pharmacology, 1996, 39, 143-149.	2.3	41

#	Article	IF	Citations
37	In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells. American Journal of Hematology, 1995, 50, 277-282.	4.1	8
38	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 34, 103-108.	2.3	9
39	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 35, 182-182.	2.3	0
40	Myelotoxicity of Rifabutin and 3’-Azido-3’-Deoxythymidine, Alone and in Combination, to Human Hematopoietic Progenitor Cells in vitro. Pathobiology, 1993, 61, 77-82.	3.8	5
41	Comparativein vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Investigational New Drugs, 1992, 10, 255-261.	2.6	19
42	Comparison of the in vitro toxicity of 2â€²,3â€²â€dideoxynucleosides to murine hematopoietic progenitor cells. International Journal of Cell Cloning, 1992, 10, 87-93.	1.6	2
43	In vitro toxicity of 3â€²â€azidoâ€3â€²â€deoxythymidine, carbovir and 2â€², 3â€²â€didehydroâ€2â€², 3â€²â€dideoxythymidine human and murine haematopoietic progenitor cells. British Journal of Haematology, 1992, 80, 437-445.	2.5	27
44	Utility of Human Bone Marrow Obtained Incidental to Orthopedic Surgery for Hematopoietic Clonal Assays. Pathobiology, 1991, 59, 53-56.	3.8	13
45	Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Investigational New Drugs, 1991, 9, 149-157.	2.6	16
46	Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. International Journal of Cell Cloning, 1989, 7, 303-313.	1.6	12
47	Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. International Journal of Cell Cloning, 1989, 7, 395-395.	1.6	7